Weight-management programs raise practical questions for med spa owners and the NPs, PAs, and other prescribers who work with them: when can a 503A pharmacy compound a GLP-1 preparation, what documentation matters, and how should a practice evaluate a pharmacy partner?

This guide focuses on the prescription workflow, patient education, and regulatory questions that practices should review before building or updating a weight-management service.

Is compounded tirzepatide still available in 2026?

Compounded tirzepatide is not a routine substitute for a commercially available product. Under section 503A, a state-licensed pharmacy compounds for an identified individual patient after receiving a valid prescription. FDA guidance says the prescriber should determine and document when a compounded preparation contains a significant difference for that patient rather than functioning as an essentially copied commercial product.

FDA’s current guidance also states that tirzepatide does not currently appear on the 503B bulks list or FDA’s drug shortage list. That means a practice should not assume that a shortage-based pathway supports a prescription. The prescriber and pharmacy should review the current legal and clinical basis for each patient-specific preparation.

How GLP-1 practices can build a clean prescribing process

A practice’s process should begin with the prescriber’s evaluation and a clear prescription. The prescription should identify the patient, requested formulation, directions, and quantity, along with the patient-specific reason a compounded preparation is being considered when that documentation is required. If the pharmacy needs clarification, the pharmacy team should contact the prescriber’s team before preparation rather than making an assumption.

Marketing should describe the practice’s consultation, monitoring, education, and communication process. It should not position a compounded preparation as a cheaper version of a brand-name drug, call it generic, or imply that it is FDA-approved. Compounded medications are patient-specific preparations and are not FDA-approved finished drug products.

Patient education also needs a defined owner. Instructions should match the actual preparation and label. Questions about treatment selection, starting or stopping therapy, dose changes, or adverse effects belong with the prescriber or pharmacist. Questions about prescription status, delivery arrangements, refills, and account information should follow the pharmacy’s approved workflow.

What to look for in a GLP-1 compounding pharmacy

Before working with a pharmacy, ask how it handles state licensure and shipping requirements for the locations where your patients live. Ask which applicable USP standards guide its work, what prescription documentation it requires, and how it labels, packages, dates, and communicates about each patient-specific preparation.

It is also reasonable to ask how patients and staff reach a pharmacist, how prescription clarifications are handled, and how the pharmacy communicates when regulations or its own procedures change. A pharmacy partner should be able to explain its process in plain language without promising results or making unsupported claims about another product.

Beyond GLP-1s: topical anesthetics and peptides

Topical anesthetics

Med spas may also ask about compounded topical anesthetics used in connection with aesthetic procedures. FDA has warned consumers about certain high-concentration over-the-counter topical pain-relief products marketed for cosmetic procedures, especially when applied over large areas, broken or irritated skin, or under coverings that can increase absorption. Any practice using a topical preparation should follow the prescription, label, prescriber direction, and its approved in-office procedures. Do not copy internet instructions onto a patient handout.

Peptides

In July 2026, an FDA Pharmacy Compounding Advisory Committee vote recommended adding several peptides, including BPC-157 and TB-500, to the 503A bulk drug substances list. That vote was a recommendation, not a final FDA rule. Pharmacies may not compound a substance under that proposed pathway until the required final rulemaking is in place. These substances are not FDA-approved finished drug products, and products labeled “research use only” are not intended for patients.

This article is general education for medical practices as of September 2026 and is not legal or medical advice. Compounded medications are patient-specific preparations and are not FDA-approved finished drug products. All formulations require a valid prescription from a licensed prescriber. Regulations change; confirm current requirements with your prescriber, pharmacist, and applicable regulatory authorities.